Huge Russian plasma products plant moving forward
25 September 2015
In May, Russia's Generium said it would build a massive blood plasma plant in the country to make antibodies, blood coagulants and albumin. Now a Swedish design firm said it starting on the engineering for the project.
Low-cost genomic sequencing on the slate for China with Veritas landing?
25 September 2015
Boston-based Veritas Genetics has set up an R&D center in China's Hangzhou Economic & Technological Development Area aimed at genomic screening and testing product development for an Asian population.
Clearside Biomedical, Inc. Announces 50th Patient Enrolled Using Suprachoroidal Drug Administration
24 September 2015
Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the retina and choroid, today announced the enrollment of the 50th patient using Clearside’s proprietary ophthalmic drug administration platform for delivering drugs to the suprachoroidal space (SCS).
China R&D innovation, investment catching up to the global markets
24 September 2015
Chinese pharmaceutical firms have come a long way, transforming themselves from makers of active pharmaceutical ingredients (APIs) to innovative drug developers in a couple of decades. The secret sauce in that transformation has been investment in R&D.
Rough waters for pharma's U.S. pricing power, yes. Sea change? Nope
24 September 2015
This could go down in pharma history as the week that drug pricing met pop culture. Social media in an uproar, headlines on Gawker and TechCrunch--even women's magazines' websites. Television and radio, too. But this week won't be remembered as the one when drugmakers lost their long-standing pricing power in the U.S.
AstraZeneca embraces crowdsourcing in a mix-and-match cancer R&D contest
24 September 2015
Hoping to spotlight some promising new combination cancer treatments, AstraZeneca ($AZN) is opening up its data vault to researchers around the globe in an effort to crowdsource new avenues for research.
Americans overpaying hugely for cancer drugs - study
24 September 2015
Americans are paying way over the odds for some modern cancer drugs, with pharmaceutical companies charging up to 600 times what the medicines cost to make, according to an independent academic study. The United States also pays more than double the price charged in Europe for these drugs - so-called tyrosine kinase inhibitors (TKIs), a potent class of cancer pills with fewer side effects than chemotherapy.
Latin America + MENA countries = opportunities, but with lots of challenges
23 September 2015
The links between the biotech sectors in Latin America and the Middle East and North Africa (MENA) remain shallow, even if industry stakeholders in both sides believe in the potential the relationships represent. Though Israel is home to some of the most sophisticated biotech companies in the region, other countries are looking to Latin America to find export markets or manufacturing locations that may be easier to tap than the more competitive and developed markets in Europe or North America.
Emerging markets, life sciences to drive renewed growth at GE Healthcare, CEO says
23 September 2015
Almost one year into the job, GE Healthcare President and CEO John Flannery recently outlined his strategy for returning the healthcare business to growth. It's an $18 billion business that accounts for about 16% of the conglomerate's total revenues. He affirmed that the business will remain within GE, despite ongoing restructuring involving the divestiture of the finance arm.
More followers and more daily tweeting as Big Pharma's Twitter presence grows
23 September 2015
Tweet on, drugmakers. Not only is Twitter use by pharma companies on the rise, but so is interest in what they've got to say. A recent survey by the Eye on FDAblog found more daily interactions on Twitter by pharma, along with a marked increase in followers versus last year.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024